

## Italian Medicines Agency

CERTIFICATE NUMBER: **IT/77/H/2024**

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

<sup>1,2</sup>

## Part 1

Issued following an inspection in accordance with  
Art. 15 of Directive 2001/20/EC as amended

The competent authority of Italy confirms the following:

The manufacturer: **Advaxia Biologics S.r.l. In Forma Abbreviata Advaxia S.r.l.**

Site address: **Via Pontina Vecchia Km 30600, Pomezia, 00071, Italy**

OMS Organisation Id. / OMS Location Id.: **ORG-100022033 / LOC-100030741**

Has been inspected under the national inspection programme in connection with manufacturing  
authorisation no. **aM-61/2024** in accordance with Art. 13 of Directive 2001/20/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted  
on **2024-02-05**, it is considered that it complies with::

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572.<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and  
should not be relied upon to reflect the compliance status if more than three years have elapsed since the date  
of that inspection. However, this period of validity may be reduced or extended using regulatory risk  
management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or  
clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>).  
This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the  
issuing authority.

<sup>1</sup>The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC is also applicable to importers.

<sup>2</sup>Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

<sup>3</sup>These requirements fulfil the GMP recommendations of WHO.

## Part 2

### Human Investigational Medicinal Products

<b>1 MANUFACTURING OPERATIONS</b>	
<b>1.1</b>	<b>Sterile products</b>
	<i>1.1.1 Aseptically prepared (processing operations for the following dosage forms)</i> 1.1.1.4 Small volume liquids
<b>1.3</b>	<b>Biological medicinal products (list of product types)</b>
	<i>1.3.1 Biological medicinal products (list of product types)</i> 1.3.1.2 Immunological products 1.3.1.4 Gene therapy products
	<i>1.3.2 Batch Certification (list of product types)</i> 1.3.2.2 Immunological products 1.3.2.4 Gene therapy products
<b>1.5</b>	<b>Packaging</b>
	<i>1.5.2 Secondary packaging</i>
<b>1.6</b>	<b>Quality control testing</b>
	<i>1.6.3 Chemical/Physical</i> <i>1.6.4 Biological</i>

Clarifying remarks (for public users)

*.1.1.4 Small volume liquids: only Immunological Products and Gene therapy products; 1.3.1.2 Immunological products: DNA vaccine (recombinant adenoviral vectors against infective agents); 1.3.1.4 Gene therapy products: Recombinant adenoviral vectors against tumour antigens; 1.3.2.2 Immunological products: aseptically prepared small volume liquids; 1.3.2.4 Genetherapy products: aseptically prepared small volume liquids; 1.6.4 Biological: "in vitro" testing, LAL test.*

2024-04-30

Name and signature of the authorised person of the  
Competent Authority of Italy

*Confidential*  
*Italian Medicines Agency*  
Tel: *Confidential*  
Fax: *Confidential*